- Home
- General Medicine
- Clinical Outcomes from the ALLEGRO Trial of Ritlecitinib in Alopecia Areata

5d3 min read
Medical Article
Introduction: Alopecia Areata (AA) is an autoimmune disease possessing immunoinflammatory mechanisms that lead to hair loss from the scalp, face, and/or body (1). Among affected patients, approximately 10-35% experience progression to more severe forms of AA (1). Moderate to severe AA has been refractory to treatment, although Janus Kinase inhibito

Clinical Outcomes from the ALLEGRO Trial of Ritlecitinib in Alopecia Areata
Similar Content

ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes

Catheter Ablation for Atrial Fibrillation with HF
691 Reached

Male Complaining of Bilateral Knee Pain and Gait Disturbance
840 Reached5 Comments1 Likes

Study evaluating Effectiveness of Bacillus clausii for Treatment of Rotavirus Infection
1303 Reached4 Comments6 Likes

Safe Ramadan Practices during COVID-19 - WHO Guidance
4865 Reached8 Comments3 Likes